Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Long-standing refractory polymyositis responding to mycophenolate mofetil: a case report and review of the literature.

Literature DB >> 17225929

Long-standing refractory polymyositis responding to mycophenolate mofetil: a case report and review of the literature.

Paola Caramaschi¹, Alessandro Volpe, Antonio Carletto, Lisa M Bambara, Domenico Biasi.

Abstract

The authors describe a young patient affected by long-standing polymyositis refractory to conventional treatment who showed a rapid and striking response to mycophenolate mofetil treatment.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2007 PMID： 17225929 DOI： 10.1007/s10067-006-0526-5

Source DB: PubMed Journal: Clin Rheumatol ISSN： 0770-3198 Impact factor: 2.980

14 in total

1. Refractory polymyositis responding to infliximab.

Authors: I Uthman; J El-Sayad
Journal: Rheumatology (Oxford) Date: 2004-09 Impact factor: 7.580

2. Refractory polymyositis responding to infliximab: extended follow-up.

Authors: I Labioche; E Liozon; B Weschler; V Loustaud-Ratti; P Soria; E Vidal
Journal: Rheumatology (Oxford) Date: 2004-04 Impact factor: 7.580

3. Advanced refractory polymyositis responding to infliximab.

Authors: A Anandacoomarasamy; G Howe; N Manolios
Journal: Rheumatology (Oxford) Date: 2005-02-03 Impact factor: 7.580

4. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis.

Authors: Johnathon C Edge; J David Outland; Jennifer R Dempsey; Jeffrey P Callen
Journal: Arch Dermatol Date: 2006-01

5. Efficacy of rituximab in refractory polymyositis.

Authors: Olivier Lambotte; Rami Kotb; Gwenola Maigne; François-Xavier Blanc; Cécile Goujard; Jean François Delfraissy
Journal: J Rheumatol Date: 2005-07 Impact factor: 4.666

6. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus.

Authors: Margaret R Wilkes; Susan M Sereika; Noreen Fertig; Mary R Lucas; Chester V Oddis
Journal: Arthritis Rheum Date: 2005-08

7. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases.

Authors: A C Gelber; H C Nousari; F M Wigley
Journal: J Rheumatol Date: 2000-06 Impact factor: 4.666

8. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.

Authors: J-E Gottenberg; L Guillevin; O Lambotte; B Combe; Y Allanore; A Cantagrel; C Larroche; M Soubrier; L Bouillet; M Dougados; O Fain; D Farge; X Kyndt; O Lortholary; C Masson; B Moura; P Remy; T Thomas; D Wendling; J-M Anaya; J Sibilia; X Mariette
Journal: Ann Rheum Dis Date: 2004-11-18 Impact factor: 19.103

9. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy.

Authors: V Majithia; V Harisdangkul
Journal: Rheumatology (Oxford) Date: 2004-11-30 Impact factor: 7.580

Review 10. Self-resolution of Epstein-Barr virus-associated B-cell lymphoma in a patient with dermatomyositis following withdrawal of mycophenolate mofetil and methotrexate.

Authors: Mark A Waldman; Jeffrey P Callen
Journal: J Am Acad Dermatol Date: 2004-08 Impact factor: 11.527

5 in total

Long-standing refractory polymyositis responding to mycophenolate mofetil: a case report and review of the literature.

1. Refractory polymyositis responding to infliximab.

2. Refractory polymyositis responding to infliximab: extended follow-up.

3. Advanced refractory polymyositis responding to infliximab.

4. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis.

5. Efficacy of rituximab in refractory polymyositis.

6. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus.

7. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases.

8. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.

9. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy.

Review 10. Self-resolution of Epstein-Barr virus-associated B-cell lymphoma in a patient with dermatomyositis following withdrawal of mycophenolate mofetil and methotrexate.

1. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis.

Review 2. [Myositides: What is the current situation?].

Review 3. Pathogenesis, classification and treatment of inflammatory myopathies.

4. Mycophenolate Mofetil-Induced Cytomegalovirus Colitis in a Patient With Polymyositis.

Review 5. Innate immune-response mechanisms in dermatomyositis: an update on pathogenesis, diagnosis and treatment.